Free Trial
NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Nuvectis Pharma logo
$7.47
-0.42 (-5.32%)
(As of 10/31/2024 ET)

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Key Stats

Today's Range
$7.16
$8.23
50-Day Range
$6.03
$8.76
52-Week Range
$5.85
$12.10
Volume
107,252 shs
Average Volume
101,816 shs
Market Capitalization
$139.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
43rd Percentile Overall Score

NVCT MarketRank™: 

Nuvectis Pharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 673rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nuvectis Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nuvectis Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.05) to ($1.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nuvectis Pharma is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nuvectis Pharma is -5.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nuvectis Pharma has a P/B Ratio of 10.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nuvectis Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    13.73% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 6.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nuvectis Pharma does not currently pay a dividend.

  • Dividend Growth

    Nuvectis Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.73% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 6.10%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nuvectis Pharma has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nuvectis Pharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for NVCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nuvectis Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.78% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nuvectis Pharma's insider trading history.
Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

NVCT Stock News Headlines

Nuvectis Pharma (NVCT) Gets a Buy from Roth MKM
Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Analyzing Nuvectis Pharma (NASDAQ:NVCT) and AbbVie (NYSE:ABBV)
See More Headlines

NVCT Stock Analysis - Frequently Asked Questions

Nuvectis Pharma's stock was trading at $8.34 at the beginning of 2024. Since then, NVCT stock has decreased by 10.4% and is now trading at $7.47.
View the best growth stocks for 2024 here
.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26).

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share.

Top institutional investors of Nuvectis Pharma include Iridian Asset Management LLC CT (0.30%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Shay Shemesh and Kenneth Hoberman.
View institutional ownership trends
.

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
8/06/2024
Today
10/31/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NVCT
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+181.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.70 per share

Miscellaneous

Free Float
11,979,000
Market Cap
$139.34 million
Optionable
Not Optionable
Beta
0.46
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:NVCT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners